Lonza Group stock holds steady as investors digest latest results

Lonza Group stock is trading steadily on the Swiss exchange as of early September 2026, with investors focusing on margins and contract development momentum after the company’s most recent reported figures and guidance.

Lonza Group (ISIN CH0013841017) stock is trading around 544.40 Swiss francs on the Swiss exchange as of September 3, 2026, giving investors a stable price backdrop while they weigh the latest reported figures and strategic developments.

Recent share price and market context

According to market data from a Swiss stock portal, Lonza Group shares last changed hands at approximately 544.40 Swiss francs on September 3, 2026, with intraday trades clustered in a narrow band between 544.40 and 544.80 Swiss francs, indicating limited short-term volatility.

This price level places the company firmly in the large-cap segment of the Swiss market, with a market capitalization comfortably in the multi-billion Swiss franc range as of early September 2026, a scale that matters for institutional investors benchmarking exposure to European healthcare and industrials.

Financial performance and margins in focus

In its most recently reported half-year results for 2026, Lonza Group has continued to underline its role as a leading contract development and manufacturing organization, with revenue in the latest reporting period compared against the prior year’s half-year level to track growth and margin trends.

Investors are paying particular attention to how Lonza’s half-year 2026 revenue compares numerically with half-year 2025, where historical figures showed a lower level, so that the current period’s revenue marks a tangible increase in absolute Swiss francs and a clear percentage uplift versus the prior year.

Equally important is profitability: operating profit and corresponding margins in half-year 2026 are assessed alongside the historical half-year 2025 reference, where margins were lower, meaning that any recent improvement in percentage points becomes a key quantified comparison for analysts following the stock.

Guidance and consensus view

For 2026 as a whole, Lonza Group has set guidance ranges covering revenue and profitability, with the midpoint of the revenue target for the fiscal year 2026 sitting comfortably above the historical revenue achieved in fiscal year 2024, signaling expected growth in billions of Swiss francs.

Analysts tracking Lonza’s shares compare this guidance midpoint with their own consensus forecasts, looking for differences measured in hundreds of millions of Swiss francs or in percentage terms, such as a guidance midpoint that stands several percentage points above the historical growth rate recorded in previous years.

On the earnings side, the focus lies on earnings per share for the most recently reported quarter and its change versus the same quarter a year earlier, where a positive delta in Swiss francs per share and in percent reflects the impact of contract wins and operational efficiency.

Contract development as core business

Lonza Group’s core business centers on contract development and manufacturing services, particularly in pharmaceuticals and biotechnology, where the company supports clients from early-stage development through to commercial-scale production.

Historically, this segment has generated a significant share of group revenue, with the most recent available segment figures showing contract development contributing a clearly dominant portion of total revenue in the latest fiscal year, measured in billions of Swiss francs and markedly above smaller legacy segments.

Stock perspective and trading venue

Lonza Group stock is listed on SIX Swiss Exchange, with trading in Swiss francs and a continuous order book that provides liquidity for both domestic and international investors as of September 3, 2026.

Lonza Group stock at a glance

• Company: Lonza Group Ltd.
• ISIN: CH0013841017
• Ticker: LONN
• Trading venue: SIX Swiss Exchange
• Price (as of September 3, 2026): 544.40 CHF
• Sector / Industry: Healthcare - Life Sciences Tools and Services
• Index membership: SMI